Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03709927 · ClinicalTrials.gov registry record · Phase 1
4-way Crossover QT Evaluation in Healthy Subjects
A Phase 1 study, sponsored by Nabriva Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT03709927 is a Phase 1 study that has completed, run by Nabriva Therapeutics. The registered enrollment target is 41 participants.
The verdict
NCT03709927, a Phase 1 study, has completed, sponsored by Nabriva Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate if ZTI-01 (fosfomycin for injection), an investigational drug being developed to treat people with complicated urinary tract and kidney infections, has any effect on the electrical activity of the heart.
Interventions
- OTHER Placebo IV
- DRUG Moxifloxacin 400mg
- DRUG ZTI-01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2018-01-11 |
| Est. Completion | 2018-08-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03709927
The ClinicalTrials.gov registry entry for NCT03709927 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nabriva Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo IV is the first listed.
NCT03709927 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03709927 about?
NCT03709927 is a clinical study titled "4-way Crossover QT Evaluation in Healthy Subjects". The purpose of this study is to evaluate if ZTI-01 (fosfomycin for injection), an investigational drug being developed to treat people with complicated urinary tract and kidney infections, has any effect on the electrical activity of the heart.
What is the current status of trial NCT03709927?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2018-01-11. Estimated completion is 2018-08-21.
What interventions are being tested in trial NCT03709927?
The interventions under investigation include: Placebo IV (OTHER), Moxifloxacin 400mg (DRUG), ZTI-01 (DRUG).
Who is sponsoring clinical trial NCT03709927?
This trial is sponsored by Nabriva Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.